The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Open accessAbstract
BACKGROUND: Respiratory tract infection with Pseudomonas aeruginosa occurs in most people with cystic fibrosis. Once chronic infection is established, Pseudomonas aeruginosa is virtually impossible to eradicate and is associated with increased mortality and morbidity. Early infection may be easier to eradicate.This is an update of a Cochrane review first published in 2003, and previously updated in 2006 and 2009. OBJECTIVES: To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement. To evaluate whether there is evidence that a particular antibiotic strategy is superior to or more cost-effective than other strategies and to compare the adverse effects of different antibiotic strategies (including respiratory infection with other micro-organisms). SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 08 September 2014. SELECTION CRITERIA: We included randomised controlled trials of people with cystic fibrosis, in whom Pseudomonas aeruginosa had recently been isolated from respiratory secretions. We compared combinations of inhaled, oral or intravenous antibiotics with placebo, usual treatment or other combinations of inhaled, oral or intravenous antibiotics. We excluded non-randomised trials, cross-over trials, and those utilising historical controls. DATA COLLECTION AND ANALYSIS: Both authors independently selected trials, assessed risk of bias and extracted data. MAIN RESULTS: The search identified 49 trials; seven trials (744 participants) with a duration between 28 days and 27 months were eligible for inclusion. Three of the trials are over 10 years old and their results may be less applicable today given the changes in standard treatment. Some of the trials had low numbers of participants and most had relatively short follow-up periods; however, there was generally a low risk of bias from missing data. In most trials it was difficult to blind participants and clinicians to treatment given the interventions and comparators used. Two trials were supported by the manufacturers of the antibiotic used.Evidence from two trials (38 participants) at the two-month time-point showed treatment of early Pseudomonas aeruginosa infection with inhaled tobramycin results in microbiological eradication of the organism from respiratory secretions more often than placebo, odds ratio 0.15 (95% confidence interval 0.03 to 0.65) and data from one of these trials, with longer follow up, suggested that this effect may persist for up to 12 months.One randomised controlled trial (26 participants) compared oral ciprofloxacin and nebulised colistin versus usual treatment. Results after two years suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than no anti-pseudomonal treatment, odds ratio 0.12 (95% confidence interval 0.02 to 0.79).One trial comparing 28 days to 56 days treatment with nebulised tobramycin solution for inhalation in 88 participants showed that both treatments were effective and well-tolerated, with no notable additional improvement with longer over shorter duration of therapy. However, this trial was not powered to detect non-inferiority or equivalence .A trial of oral ciprofloxacin with inhaled colistin versus nebulised tobramycin solution for inhalation alone (223 participants) failed to show a difference between the two strategies, although it was underpowered to show this. A further trial of inhaled colistin with oral ciprofloxacin versus nebulised tobramycin solution for inhalation with oral ciprofloxacin also showed no superiority of the former, with increased isolation of Stenotrophomonas maltophilia in both groups.A recent, large trial in 306 children aged between one and 12 years compared cycled nebulised tobramycin solution for inhalation to culture-based therapy and also ciprofloxacin to placebo. The primary analysis showed no difference in time to pulmonary exacerbation or proportion of Pseudomonas aeruginosa positive cultures. An analysis performed in this review (not adjusted for age) showed fewer participants in the cycled therapy group with one or more isolates of Pseudomonas aeruginosa, odds ratio 0.51 (95% CI 0.31 to 0.28). AUTHORS' CONCLUSIONS: We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection with Pseudomonas aeruginosa. Eradication may be sustained for up to two years. There is insufficient evidence to determine whether antibiotic strategies for the eradication of early Pseudomonas aeruginosa decrease mortality or morbidity, improve quality of life, or a
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
(2008) · Cited by 3,790
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007
The changing epidemiology of cystic fibrosis
FitzSimmons, S. C. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83478-x · Cited by 928
Lee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M., & Littlewood, J. M. (2003) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00141-8 · Cited by 713
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Döring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Høiby, N., Smyth, A., Touw, D. J., & the Consensus Committee, F. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.16d30.x · Cited by 620
Self-citationEuropean cystic fibrosis society standards of care: best practice guidelines
Smyth, A. R., Bell, S. C., Bojcin, S., Bryon, M., Duff, A., Flume, P., Kashirskaya, N., Munck, A., Ratjen, F., Schwarzenberg, S. J., et al. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.03.010 · Cited by 582
Self-citationLongitudinal Assessment of Pseudomonas aeruginosa in Young Children with Cystic Fibrosis
Burns, J. L., Gibson, R. L., McNamara, S., Yim, D., Emerson, J., Rosenfeld, M., Hiatt, P., McCoy, K., Castile, R., Smith, A. L., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/318075 · Cited by 555
Management of Pulmonary Disease in Patients with Cystic Fibrosis
Ramsey, B. W. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607183350307 · Cited by 502
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
Valerius, N. H., Koch, C., & Høiby, N. (1991) · The Lancet · doi:10.1016/0140-6736(91)91446-2 · Cited by 475
Treatment of lung infection in patients with cystic fibrosis: Current and future strategies
Döring, G., Flume, P., Heijerman, H., & Elborn, J. S. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.10.004 · Cited by 474
Frederiksen, B., Koch, C., & Høiby, N. (1997) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o · Cited by 473
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis
Nixon, G. M., Armstrong, D. S., Carzino, R., Carlin, J. B., Olinsky, A., Robertson, C. F., & Grimwood, K. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.112897 · Cited by 432
Kosorok, M. R., Zeng, L., West, S. E. H., Rock, M. J., Splaingard, M. L., Laxova, A., Green, C. G., Collins, J., & Farrell, P. M. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.2009.abs · Cited by 400
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis*
Rosenfeld, M., Gibson, R. L., McNamara, S., Emerson, J., Burns, J. L., Castile, R., Hiatt, P., McCoy, K., Wilson, C. B., Inglis, A., et al. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.1144 · Cited by 395
Quantitation of Inflammatory Responses to Bacteria in Young Cystic Fibrosis and Control Patients
MUHLEBACH, M. S., STEWART, P. W., LEIGH, M. W., & NOAH, T. L. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.1.9808096 · Cited by 354
Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Gibson, R. L., Emerson, J., McNamara, S., Burns, J. L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-855oc · Cited by 318
Konstan, M. W., Flume, P. A., Kappler, M., Chiron, R., Higgins, M., Brockhaus, F., Zhang, J., Angyalosi, G., He, E., & Geller, D. E. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2010.10.003 · Cited by 314
Coming together: the ATS/ERS consensus on clinical pulmonary function testing
Brusasco, V., Crapo, R., & Viegi, G. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034205 · Cited by 313
Defining a pulmonary exacerbation in cystic fibrosis
Rosenfeld, M., Emerson, J., Williams-Warren, J., Pepe, M., Smith, A., Montgomery, A. B., & Ramsey, B. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.117288 · Cited by 302
Armstrong, D. S., Grimwood, K., Carlin, J. B., Carzino, R., Olinsky, A., & Phenlan, P. D. (1996) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199605)21:5<267::aid-ppul1>3.0.co;2-k · Cited by 301
Pharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis
Geller, D. E., Pitlick, W. H., Nardella, P. A., Tracewell, W. G., & Ramsey, B. W. (2002) · Chest · doi:10.1378/chest.122.1.219 · Cited by 300
Ratjen, F., Munck, A., Kho, P., Angyalosi, G., & for the ELITE Study Group (2010) · Thorax · doi:10.1136/thx.2009.121657 · Cited by 291
Burns, J. L., Van Dalfsen, J. M., Shawar, R. M., Otto, K. L., Garber, R. L., Quan, J. M., Montgomery, A. B., Albers, G. M., Ramsey, B. W., & Smith, A. L. (1999) · The Journal of Infectious Diseases · doi:10.1086/314727 · Cited by 289
Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
Retsch-Bogart, G. Z., Quittner, A. L., Gibson, R. L., Oermann, C. M., McCoy, K. S., Montgomery, A. B., & Cooper, P. J. (2009) · Chest · doi:10.1378/chest.08-1421 · Cited by 281
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Ratjen, F., Döring, G., & Nikolaizik, W. H. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06124-4 · Cited by 218
Treggiari, M. M., Retsch-Bogart, G., Mayer-Hamblett, N., Khan, U., Kulich, M., Kronmal, R., Williams, J., Hiatt, P., Gibson, R. L., Spencer, T., et al. (2011) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2011.136 · Cited by 215
Schuster, A., Haliburn, C., Döring, G., Goldman, M. H., & for the Freedom Study Group (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202059 · Cited by 208
NEBULISED COLOMYCIN FOR EARLY PSEUDOMONAS COLONISATION IN CYSTIC FIBROSIS
Littlewood, J. M., Miller, M. G., Ghoneim, A. T., & Ramsden, C. H. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92222-6 · Cited by 203
Wiesemann, H. G., Steinkamp, G., Ratjen, F., Bauernfeind, A., Przyklenk, B., Döring, G., & von der Hardt, H. (1998) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199802)25:2<88::aid-ppul3>3.0.co;2-j · Cited by 200
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
Geller, D. E., Konstan, M. W., Smith, J., Noonberg, S. B., & Conrad, C. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20594 · Cited by 196
Oermann, C. M., Retsch‐Bogart, G. Z., Quittner, A. L., Gibson, R. L., McCoy, K. S., Montgomery, A. B., & Cooper, P. J. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21301 · Cited by 187
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients
Taccetti, G., Campana, S., Festini, F., Mascherini, M., & Döring, G. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00009605 · Cited by 181
Wainwright, C. E., Vidmar, S., Armstrong, D. S., Byrnes, C. A., Carlin, J. B., Cheney, J., Cooper, P. J., Grimwood, K., Moodie, M., Robertson, C. F., et al. (2011) · JAMA · doi:10.1001/jama.2011.954 · Cited by 180
Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis
Douglas, T. A., Brennan, S., Gard, S., Berry, L., Gangell, C., Stick, S. M., Clements, B. S., & Sly, P. D. (2009) · European Respiratory Journal · doi:10.1183/09031936.00043108 · Cited by 167
(2004) · Die Rehabilitation · doi:10.1055/s-2004-818553 · Cited by 167
Stutman, H. R., Lieberman, J. M., Nussbaum, E., & Marks, M. I. (2002) · The Journal of Pediatrics · doi:10.1067/mpd.2002.121930 · Cited by 166
Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial
Konstan, M. W., Geller, D. E., Minić, P., Brockhaus, F., Zhang, J., & Angyalosi, G. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21356 · Cited by 166
Long-term Benefits of Inhaled Tobramycin in Adolescent Patients With Cystic Fibrosis
Moss, R. B. (2002) · CHEST Journal · doi:10.1378/chest.121.1.55 · Cited by 156
Geller, D. E., Flume, P. A., Staab, D., Fischer, R., Loutit, J., & Conrad, D. J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201008-1293oc · Cited by 150
Abman, S. H., OGLE, J., Harbeck, R. J., Butler–Simon, N., HAMMOND, K., & Accurso, F. J. (1991) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80729-2 · Cited by 149
Parad, R. B., Gerard, C. J., Zurakowski, D., Nichols, D. P., & Pier, G. B. (1999) · Infection and Immunity · doi:10.1128/iai.67.9.4744-4750.1999 · Cited by 143
Treggiari, M. M., Rosenfeld, M., Mayer-Hamblett, N., Retsch‐Bogart, G. Z., Gibson, R. L., Williams, J., Emerson, J., Kronmal, R. A., & Ramsey, B. W. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.01.003 · Cited by 141
Høiby, N. (1974) · Acta Pathologica Microbiologica Scandinavica Section B Microbiology and Immunology · doi:10.1111/j.1699-0463.1974.tb02365.x · Cited by 137
Hudson, V. L., Wielinski, C. L., & Regelmann, W. E. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(09)90007-5 · Cited by 133
Trapnell, B. C., McColley, S. A., Kissner, D. G., Rolfe, M. W., Rosen, J. M., McKevitt, M. T., Moorehead, L., Montgomery, A. B., & Geller, D. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0924oc · Cited by 129
Ratjen, F. A., Comes, G., Paul, K. P., Posselt, H., Wagner, T. O. F., Harms, K., & for the German Board of the European Registry for Cystic Fibrosis (ERCF) (2001) · Pediatric Pulmonology · doi:10.1002/1099-0496(200101)31:1<13::aid-ppul1001>3.0.co;2-n · Cited by 129
Retsch‐Bogart, G. Z., Burns, J. L., Otto, K., Liou, T. G., McCoy, K., Oermann, C. M., Gibson, R. L., & AZLI Phase II Study Group (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20736 · Cited by 107
Taccetti, G., Bianchini, E., Cariani, L., Buzzetti, R., Costantini, D., Trevisan, F., Zavataro, L., & Campana, S. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-200832 · Cited by 104
Proesmans, M., Vermeulen, F. L., Boulanger, L., Verhaegen, J., & Boeck, K. D. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.06.001 · Cited by 103
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Hewer, S. C. L., & Smyth, A. R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub3 · Cited by 103
Self-citationRespiratory Tract Bacteriology in Cystic Fibrosis
Iacocca, V. F. (1963) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1963.02080050317012 · Cited by 100
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Walters, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912 · Cited by 100
Self-citationAdministration of Aerosolized Antibiotics in Cystic Fibrosis Patients
Moss, R. B. (2001) · CHEST Journal · doi:10.1378/chest.120.3_suppl.107s · Cited by 98
Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis
Thomassen, M. J., Klinger, J. D., Badger, S. J., van Heeckeren, D. W., & Stern, R. C. (1984) · The Journal of Pediatrics · doi:10.1016/s0022-3476(84)81094-x · Cited by 98
Byrnes, C. A., Vidmar, S., Cheney, J. L., Carlin, J. B., Armstrong, D., Cooper, P., Grimwood, K., Moodie, M., ROBERTSON, C. F., Rosenfeld, M., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202342 · Cited by 97
MacLeod, D. L., Nelson, L. E., Shawar, R. M., Lin, B. B., Lockwood, L. G., Dirk, J. E., Miller, G. H., Burns, J. L., & Garber, R. L. (2000) · The Journal of Infectious Diseases · doi:10.1086/315312 · Cited by 95
Wainwright, C. E., Quittner, A. L., Geller, D. E., Nakamura, C., Wooldridge, J. L., Gibson, R. L., Lewis, S., & Montgomery, A. B. (2011) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.02.007 · Cited by 94
Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis
Alothman, G. A., Ho, B., Alsaadi, M. M., Ho, S. L., O'Drowsky, L., Louca, E., & Coates, A. L. (2005) · CHEST Journal · doi:10.1378/chest.127.2.522 · Cited by 92
Ciofu, O., Mandsberg, L. F., Wang, H., & Høiby, N. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00983.x · Cited by 92
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Rosenfeld, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912.pub4 · Cited by 91
Self-citationInitial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
Mayer-Hamblett, N., Kronmal, R. A., Gibson, R. L., Rosenfeld, M., Retsch‐Bogart, G. Z., Treggiari, M. M., Burns, J. L., Khan, U., Ramsey, B. W., & for the EPIC Investigators (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21525 · Cited by 89
Ballmann, M., Rabsch, P., & von der Hardt, H. (1998) · Thorax · doi:10.1136/thx.53.9.732 · Cited by 84
Lee, T. W. R., Brownlee, K. G., Denton, M., Littlewood, J. M., & Conway, S. P. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.10401 · Cited by 84
Mainz, J. G., Schädlich, K., Schien, C., Michl, R., Schelhorn-Neise, P., Koitschev, A., Koitschev, C., Riethmueller, J., Wiedemann, B., Beck, J. F., et al. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s54064 · Cited by 82
Lenoir, G., Antypkin, Y. G., Miano, A., Moretti, P., Zanda, M., Varoli, G., Preti, P. A. M., & Aryayev, N. L. (2007) · Pediatric Drugs · doi:10.2165/00148581-200709001-00003 · Cited by 82
Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years
Kidd, T. J., Ramsay, K. A., Vidmar, S., Carlin, J. B., Bell, S. C., Wainwright, C. E., Grimwood, K., Francis, P. W., Dakin, C., Cheney, J. L., et al. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.12.007 · Cited by 80
Microbiological and Immunologic Considerations With Aerosolized Drug Delivery
LiPuma, J. J. (2001) · CHEST Journal · doi:10.1378/chest.120.3_suppl.118s · Cited by 79
Mayer-Hamblett, N., Kloster, M., Rosenfeld, M., Gibson, R. L., Retsch‐Bogart, G. Z., Emerson, J., Thompson, V., & Ramsey, B. W. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ377 · Cited by 78
Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial
Mainz, J. G., Schiller, I., Ritschel, C., Mentzel, H., Riethmüller, J., Koitschev, A., Schneider, G., Beck, J. F., & Wiedemann, B. (2010) · Auris Nasus Larynx · doi:10.1016/j.anl.2010.09.001 · Cited by 77
Flume, P. A., VanDevanter, D. R., Morgan, E. E., Dudley, M. N., Loutit, J., Bell, S. C., Kerem, E., Fischer, R., Smyth, A. R., Aaron, S. D., et al. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.12.004 · Cited by 77
Self-citationElborn, J. S., Geller, D. E., Conrad, D. J., Aaron, S. D., Smyth, A. R., Fischer, R., Kerem, E., Bell, S. C., Loutit, J., Dudley, M. N., et al. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.12.013 · Cited by 74
Self-citationClinic and radiological improvement of lipoid pneumonia with multiple bronchoalveolar lavages
Sias, S. M. A., Daltro, P. A. N., Marchiori, E. D. S., Ferreira, Â. S., Caetano, R., Silva, C. S., Müller, N. L., Moreira, J. D. S., & Quírico‐Santos, T. (2009) · Pediatric Pulmonology · doi:10.1002/ppul.20918 · Cited by 74
Quittner, A. L., & Buu, A. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10074 · Cited by 71
Alothman, G. A., Alsaadi, M. M., Ho, B., Ho, S. L., Dupuis, A., Corey, M. L., & Coates, A. L. (2002) · CHEST Journal · doi:10.1378/chest.122.3.930 · Cited by 70
Staß, H., Weimann, B., Nagelschmitz, J., Rolinck‐Werninghaus, C., & Staab, D. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.003 · Cited by 65
Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis
Schaad, U. B., Wedgwood, J., Rüdeberg, A., Kraemer, R., & Hampel, B. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199701000-00032 · Cited by 61
Regnault, A., Balp, M., Kulich, K. R., & Viala-Danten, M. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.04.007 · Cited by 58
Heinzl, B., Eber, E., Oberwaldner, B., Haas, G., & Zach, M. S. (2001) · Pediatric Pulmonology · doi:10.1002/ppul.10019 · Cited by 58
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Wood, D. M., & Smyth, A. R. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub2 · Cited by 56
Self-citationSafety of bronchoalveolar lavage in young children with cystic fibrosis
Wainwright, C. E., Grimwood, K., Carlin, J. B., Vidmar, S., Cooper, P. J., Francis, P. W., Byrnes, C. A., Whitehead, B., Martin, A. J., Robertson, I. F., et al. (2008) · Pediatric Pulmonology · doi:10.1002/ppul.20885 · Cited by 54
Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients
Kerem, E., Corey, M., Stein, R. T., et al. (1990) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199007000-00008 · Cited by 53
Elborn, J. S., Flume, P. A., Cohen, F. J., Loutit, J., & VanDevanter, D. R. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.01.005 · Cited by 52
Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrenty wheezy infants
Mœller, A., Franklin, P., Hall, G. L., Turner, S., Straub, D. A., Wildhaber, J. H., & Stick, S. M. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.20055 · Cited by 51
Coates, A. L., Denk, O., Leung, K., Ribeiro, N., Chan, J., Green, M., Martin, S., Charron, M., Edwardes, M., & Keller, M. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21376 · Cited by 49
Noah, T. L., Ivins, S. S., Abode, K. A., Stewart, P. W., Michelson, P. H., Harris, W. T., Henry, M. M., & Leigh, M. W. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21176 · Cited by 48
Staß, H., Delesen, H., Nagelschmitz, J., & Staab, D. (2014) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2013.1056 · Cited by 46
Physician‐diagnosed asthma and acute chest syndrome: Associations with NOS Polymorphisms
Duckworth, L. J., Hsu, L. L.-Y., Feng, H., Wang, J., Sylvester, J. E., Kissoon, N. “., Sandler, E. S., & Lima, J. J. (2007) · Pediatric Pulmonology · doi:10.1002/ppul.20582 · Cited by 44
Ruddy, J. R., Emerson, J., Moss, R. B., Genatossio, A., McNamara, S., Burns, J. L., Anderson, G. D., & Rosenfeld, M. (2012) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2011.0942 · Cited by 44
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Anstead, M., Heltshe, S. L., Khan, U., Barbieri, J. T., Langkamp, M., Döring, G., Dharia, S., Gibson, R. L., Treggiari, M. M., Lymp, J. F., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.08.001 · Cited by 43
Tramper‐Stranders, G. A., Wolfs, T. F. W., Noman, S. V. H., van Aalderen, W. M. C., Nagelkerke, A. F., Nuijsink, M., Kimpen, J. L. L., & van der Ent, C. K. (2010) · Thorax · doi:10.1136/thx.2009.126128 · Cited by 43
Tobramycin Inhalation Powder in Cystic Fibrosis Patients: Response by Age Group
Geller, D. E., Nasr, S. Z., Piggott, S., He, E., Angyalosi, G., & Higgins, M. (2013) · Respiratory Care · doi:10.4187/respcare.02264 · Cited by 40
Latzin, P., Fehling, M., Bauernfeind, A., Reinhardt, D., Kappler, M., & Griese, M. (2007) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2007.07.001 · Cited by 37
Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis
Mayer-Hamblett, N., Rosenfeld, M., Treggiari, M. M., Konstan, M. W., Retsch‐Bogart, G. Z., Morgan, W. J., Wagener, J. S., Gibson, R. L., Khan, U., Emerson, J., et al. (2013) · Pediatric Pulmonology · doi:10.1002/ppul.22693 · Cited by 36
The long-term use of inhaled tobramycin in patients with cystic fibrosis
Bowman, C. M. (2002) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00003-6 · Cited by 35
Aztreonam Lysine for Inhalation Solution: In Cystic Fibrosis
Plosker, G. L. (2010) · Drugs · doi:10.2165/10484070-000000000-00000 · Cited by 33
Griffith, P. C., Hansen, C., Pressler, T., Baichen, T., Jensen, T. J., Geller, D. E., Kesser, K. C., Rock, J., Surber, M. W., Bostian, K. A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(08)60101-0 · Cited by 29
LeLorier, J., Perreault, S., Birnbaum, H., Greenberg, P. E., & Sheehy, O. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)87985-0 · Cited by 28
Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis
Kenny, S. L., Shaw, T. D., Downey, D. G., Moore, J. E., Rendall, J. C., & Elborn, J. S. (2014) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2014-000021 · Cited by 28
Stockmann, C. R., Hillyard, B., Ampofo, K., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.986469 · Cited by 27
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
Smyth, A. R., & Walters, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001912.pub2 · Cited by 27
Self-citationRandomized Trials Stopped Early for Benefit: A Systematic Review
Montori, V. M., Devereaux, P. J., Adhikari, N. K. J., Burns, K. E. A., Eggert, C. H., Briel, M., Lacchetti, C., Leung, T. W., Darling, E., Bryant, D. M., et al. (2005) · JAMA · doi:10.1001/jama.294.17.2203 · Cited by 26
Dupont, L., Minic, P. B., Fustic, S., Mazurek, H., Sólyom, E., Feketova, A., Csiszér, E., & Gupta, R. (2008) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(08)60099-5 · Cited by 25
Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ciprofloxacin
Proesmans, M., Boulanger, L., Vermeulen, F. L., & Boeck, K. D. (2008) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(08)60246-5 · Cited by 24
Keller, M., Coates, A. L., Griese, M., Denk, O., Schierholz, J. M., & Knoch, M. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60085-9 · Cited by 24
Moodie, M., Lal, A., Vidmar, S., Armstrong, D., Byrnes, C. A., Carlin, J. B., Cheney, J. L., Cooper, P. J., Grimwood, K., ROBERTSON, C. F., et al. (2014) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2014.05.031 · Cited by 19
Wainwright, C. E., Nakamura, C., Geller, D. E., & Montgomery, A. B. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60082-3 · Cited by 19
Oermann, C. M., McCoy, K., Retsch‐Bogart, G. Z., Gibson, R. L., & Montgomery, A. B. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60111-9 · Cited by 19
Kearns, G. L., Rubino, C. M., Griffith, D. C., Geller, D. E., Forrest, A., Bhavnani, S. M., Loutit, J., Ambrose, P. G., & Dudley, M. N. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60106-9 · Cited by 19
Flume, P. A., Geller, D. E., Sindel, L. J., Staab, D., Fischer, R., Riethmüller, J., Loutit, J., & Conrad, D. J. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60087-2 · Cited by 18
Ratjen, F. A., Stenglein, S., & Munck, À. (2008) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(08)60098-3 · Cited by 17
Denk, O., Coates, A. L., Keller, M., Leung, K., Green, M., Chan, J., Ribeiro, N., & Charron, M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60261-7 · Cited by 17
Ratjen, E., Munck, À., & Campello, V. (2006) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(06)80085-8 · Cited by 17
Mazurek, H., Lenoir, G., Pelikán, L., Geidel, C., Bolbas, K., Antipkin, Y., Blanco, M., Varoli, G., Gandini, G., CICIRELLO, H. G., et al. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60127-6 · Cited by 17
Cheney, J. L., Vidmar, S., Grimwood, K., Carlin, J. B., & Wainwright, C. E. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60157-0 · Cited by 16
Treggiari, M., Retsch-Bogart, G., Mayer-Hamblett, N., Khan, U., Kronmal, R., Ramsey, B. W., & Accurso, F. J. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60210-x · Cited by 15
Conrad, D., Flume, P. A., Sindel, L. J., Andrews, S., Morgan, L., Loutit, J., & Geller, D. E. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a2339 · Cited by 15
Elborn, J. S., Geller, D., Conrad, D. J., Aaron, S. D., Smyth, A. R., Fischer, R., Kerem, E., Bell, S. C., Loutit, J., & Flume, P. A. (2013) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(13)60108-3 · Cited by 14
Self-citationKonstan, M. W., Flume, P. A., Brockhaus, F., Angyalosi, G., He, E., & Geller, D. E. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60083-5 · Cited by 14
Cheney, J. L., & Wainwright, C. E. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60452-3 · Cited by 14
Flume, P. A., VanDevanter, D. R., Cohen, F. J., Fleming, R., & Elborn, J. S. (2015) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(15)30294-0 · Cited by 13
238. Treatment for exacerbations only does not arrest progressive lung function decline in CF
QUAN, J. (1999) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(99)90290-5 · Cited by 13
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.
Hazinski, T. A. (1999) · PubMed · Cited by 13
Kylstra, J. W. (1999) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(99)90288-7 · Cited by 12
Flume, P. A., Geller, D. E., Loutit, J., Dudley, M. N., & Conrad, D. J. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60105-7 · Cited by 12
Aspiration: A common event and a clinical challenge
Colombo, J. L., & Hallberg, T. K. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21560 · Cited by 12
Geller, D. E., Flume, P. A., Brockhaus, F., Zhang, J., Angyalosi, G., He, E., & Konstan, M. W. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60084-7 · Cited by 12
Steinkamp, G., Schmitt‐Grohé, S., Döring, G., Worlitzsch, D., Staab, D., Schubert, R., & Zielen, S. (2006) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(06)80098-6 · Cited by 12
Dupont, L., Clancy, J. P., Minic, P. B., Goss, C. H., Fustic, S., Mazurek, H., Nick, J. A., Billings, J. L., Rubenstein, R. C., Sólyom, E., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1836 · Cited by 12
Mainz, J. G., Schien, C., Schädlich, K., Pfister, W., Schelhorn-Neise, P., Koitschev, A., Riethmüller, J., Wiedemann, B., & Beck, J. F. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60101-x · Cited by 11
Regnault, A., Balp, M. M., Kulich, K. R., Estève, L., & Viala-Danten, M. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60345-7 · Cited by 11
Mazurek, H., Chiron, R., Pelikán, L., Geidel, C., Bolbas, K., Antipkin, Y., Blanco, M., Varoli, G., Santoro, D., CICIRELLO, H. G., et al. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60128-8 · Cited by 11
Konstan, M. W., Geller, D. E., Minic, P., Brockhaus, F., Zhang, J., & Angyalosi, G. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60109-0 · Cited by 11
Regnault, A., Balp, M., Kulich, K. R., Estève, L., & Viala-Danten, M. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60336-6 · Cited by 11
Lenoir, G., Aryayev, N., Varoli, G., & Preti, P. M. (2006) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(06)80166-9 · Cited by 11
McCoy, K., Retsch‐Bogart, G. Z., Gibson, R. L., Oermann, C. M., McKevitt, M., & Montgomery, A. B. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60112-0 · Cited by 10
Pharmacokinetics of continuous treatment with o.d. or b.i.d. inhalation of tobramycin (TOBI™)
Rietschel, E., Staab, D., von Konigsbruggen, S., Merkel, N., Heuer, H.-E., & Posselt, H. (2010) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(10)60086-0 · Cited by 10
Goldman, M., Schuster, A., Haliburn, C., & Döring, G. (2012) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(12)60038-1 · Cited by 10
Flume, P. A., Elborn, J. S., Polu, K. R., Llorens, L., Pecoraro, M. L., Bhatt, N., & VanDevanter, D. R. (2016) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(16)30278-8 · Cited by 10
Wainwright, C., Kidd, T., Ramsey, K., et al. (2011) · Pediatric Pulmonology · Cited by 10
Rietschel, E., Posselt, H., Heuer, H.-J., Merkel, N., & Staab, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60110-7 · Cited by 9
Tramper‐Stranders, G. A., Wolfs, T. F. W., van Aalderen, W. M. C., Kouwenberg, J. M., Nagelkerke, A. F., & van der Ent, C. K. (2009) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(09)60148-x · Cited by 9
102* Eradication of recent Pseudomonas aeruginosa infection: TOBI versus Colistineb®/ciprofloxacin
Proesmans, M., Boulanger, L., Vermeulen, F. L., & Boeck, K. D. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60119-7 · Cited by 8
42 Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial
Chiron, R., Geller, D. E., Angyalosi, G., DeBonnett, L., Yadao, A. M., Bader, G., & Konstan, M. W. (2014) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(14)60179-x · Cited by 8
Elborn, J. S., Flume, P. A., Loutit, J., & Cohen, F. J. (2014) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(14)60050-3 · Cited by 8
Geller, D. E., Flume, P. A., Konstan, M. W., Angyalosi, G., & Higgins, M. D. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60100-8 · Cited by 8
Mazurek, H., Chiron, R., Varoli, G., Santoro, D., CICIRELLO, H. G., & Antipkin, Y. (2012) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(12)60239-2 · Cited by 8
Schuster, A., Pressler, T., Zhu, H., & Haberman, R. J. (2015) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(15)30295-2 · Cited by 7
Cited by
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Self-citationThe Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Winstanley, C., O’Brien, S., & Brockhurst, M. A. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.01.008 · Cited by 689
Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N., Nordmann, P., Plésiat, P., Roussel-Delvallez, M., Van Eldere, J., Glupczynski, Y., Van Laethem, Y., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Metadata
- Authors
- Langton Hewer, S. C., & Smyth, A. R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2014-11-10
- Volume
- 4
- Issue
- 11
- Pages
- CD004197-CD004197
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2107219222
- Cited by
- 324
- References
- 155
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.